scholarly journals CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients

Biomedicines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1249
Author(s):  
Gabriela M Almeida ◽  
Carla Pereira ◽  
Ji-Hyeon Park ◽  
Carolina Lemos ◽  
Sofia Campelos ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Therapy Response ◽  
Predictive Marker ◽  
Response To Treatment ◽  
Depth Of Invasion ◽  
Conventional Chemotherapy ◽  
Tumor Expression ◽  
Gastric Cancer Patients ◽  
Selection Of ◽  
Cd44v6 Expression

In gastric cancer (GC), biomarkers that define prognosis and predict treatment response remain scarce. We hypothesized that the extent of CD44v6 membranous tumor expression could predict prognosis and therapy response in GC patients. Two GC surgical cohorts, from Portugal and South Korea (n = 964), were characterized for the extension of CD44v6 membranous immuno-expression, clinicopathological features, patient survival, and therapy response. The value of CD44v6 expression in predicting response to treatment and its impact on prognosis was determined. High CD44v6 expression was associated with invasive features (perineural invasion and depth of invasion) in both cohorts and with worse survival in the Portuguese GC cohort (HR 1.461; 95% confidence interval 1.002–2.131). Patients with high CD44v6 tumor expression benefited from conventional chemotherapy in addition to surgery (p < 0.05), particularly those with heterogeneous CD44v6-positive and -negative populations (CD44v6_3+) (p < 0.007 and p < 0.009). Our study is the first to identify CD44v6 high membranous expression as a potential predictive marker of response to conventional treatment, but it does not clarify CD44v6 prognostic value in GC. Importantly, our data support selection of GC patients with high CD44v6-expressing tumors for conventional chemotherapy in addition to surgery. These findings will allow better stratification of GC patients for treatment, potentially improving their overall survival.

scholarly journals CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients

2018 ◽  
Author(s):  
Carla Pereira ◽  
Daniel Ferreira ◽  
Carolina Lemos ◽  
Diana Martins ◽  
Nuno Mendes ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Poor Prognosis ◽  
Treatment Options ◽  
Therapy Response ◽  
Predictive Marker ◽  
Response To Therapy ◽  
Conventional Chemotherapy ◽  
Poor Overall Survival ◽  
Cd44v6 Expression

AbstractLate diagnosis, modest treatment options and lack of predictive markers of therapy response dictate the poor overall survival (OS) of ∼1 year in most gastric cancer (GC) patients. We hypothesized that the level of CD44v6 expression in tumor cells could predict therapy response and prognosis in GC patients.We analyzed a surgical tumor series of GC patients for the extension of CD44v6 membranous immuno-expression, clinical-pathological features, patient survival, and response to therapy. By integrating this information, we assessed the value of CD44v6 expression to predict benefit from current treatment regimens and prognosis in GC patients. We used GC cell lines and mouse xenografts to assess and/validate the biological impact of CD44v6 expression in GC cells behavior.We demonstrated that GC patients whose tumors present higher levels of CD44v6 membranous expression benefit from adding chemotherapy to surgery as opposed to those without CD44v6 expression. Moreover, patients bearing CD44_high tumors presented worse OS than those bearing CD44_absent/low tumors, consolidating the role of CD44v6 expression as an independent factor of poor prognosis in this disease. Finally, ourin vitroand patients’ data pinpoints the CD44v6+ cell population as the driver of tumor recurrence following conventional chemotherapy, in heterogeneous tumors composed by CD44v6- and CD44v6+ cells.Our study pioneers the identification of CD44v6 as a potential predictive marker of response to conventional chemotherapy, and consolidates CD44v6 as an independent marker of poor prognosis in GC. Overall, our data strongly supports selection of patients with high CD44v6 expressing tumors for conventional chemotherapy with or without surgery, regardless of the TNM stage.

Preoperative level of VEGF and IL-6 are associated with lymph node invasion and stage in gastric cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4626-4626
Author(s):  
S. OH ◽  
H. Kwon ◽  
H. Yoo ◽  
S. Lee ◽  
S. Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Tumor Invasion ◽  
Predictive Marker ◽  
Depth Of Invasion ◽  
Vascular Structure ◽  
Preoperative Level ◽  
Gastric Cancer Patients ◽  
Vegf Level

4626 Introduction: Angiogenesis plays an important role in growth, progression, and metastasis of tumors, and various cytokines are associated with the spread of cancer cell. In this study, we evaluate the role of VEGF and IL-6 in predicting the spread of gastric cancer. Methods: Preoperative one hundred twenty seven gastric cancer patients and 88 healthy subjects’ specimens were examined. The association of VEGF and IL-6 level with clinical and pathological findings was evaluated Results: Serum VEGF and IL-6 level in gastric cancer patients were higher than those in control (P<0.001, P=0.006, respectively). VEGF and IL-6 level were associated with presence of LN metastasis (P=0.003, P=0.041, respectively). IL-6 level was correlated with stage (P=0.012) and depth of invasion (P=0.018). VEGF level was correlated with invasion of lympho-vascular structure (P=0.021). VEGF and IL-6 level was not related to differentiation, size or CEA level. Conclusions: Serum VEGF and IL-6 levels in gastric cancer patients are higher than those in control. Preoperative VEGF and IL-6 levels could be a predictive marker of tumor invasion and LN metastasis. No significant financial relationships to disclose.

The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-florouracil (DCF) regimen.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15191-e15191
Author(s):  
Sedef H. Aktas ◽  
Hakan Akbulut ◽  
Ozan Yazici ◽  
Nurullah Zengin ◽  
Nalan Akgun ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Predictive Marker ◽  
Vascular Endothelial ◽  
Gastric Cancer Patients ◽  
Endothelial Growth Factor

e15191 Background: Vascular endothelial growth factor (VEGF) is a key element stimulating the angiogenesis in solid tumors. In the current study, we aimed to assess the role of plasma VEGF levels as a prognostic and predictive marker for advanced gastric cancer patients treated with a modified docetaxel, cisplatinum and 5-florouracil (DCF) regimen. Methods: Thirty consecutive patients treated with a modified DCF regimen were included in the study. The plasma VEGF levels of the patients before treatment and following two cycles of chemotherapy were assayed. Results: The modified DCF regimen was well tolerated and yielded a median overall survival (OS) time of 9,0 months and 2-year OS rate of 20%. Good performance status, lower pre-treatment VEGF levels,and decrease in VEGF levels following chemotherapy were found to be independent prognostic factors for OS. Conclusions: The results of the current study suggest that the corrected plasma levels of VEGF could be used as a prognostic factor for advanced gastric cancer patients and a decrease in VEGF levels following 2 cycles of chemotherapy as a predictive marker for patients receiving DCF chemotherapy regimen.

Association of CDH1 mutation with prognosis in gastric adenocarcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15514-e15514
Author(s):  
Xiangyang Yu ◽  
Shimin Yang ◽  
Rong Du ◽  
Jingbo Zhang ◽  
Nan Fang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Stomach Cancer ◽  
Gastric Adenocarcinoma ◽  
Tumor Metastasis ◽  
Gene Mutations ◽  
Predictive Marker ◽  
Synonymous Mutations ◽  
Cdh1 Mutation ◽  
Gastric Cancer Patients

e15514 Background: Stomach cancer is a major cause of cancer death in East Asia. The purpose of this study was to find a predictive marker to estimate the prognosis of stomach cancer. Methods: In this study, a total of 34 gastric cancer patients receiving therapy in Tianjin Nankai Hospital were enrolled. Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue sections, including carcinoma and pericarcinous tissues. Targeted regions of 549 cancer-associated genes were amplified by PCR, barcoded and sequenced using an Illumina Next-Seq 500 platform. Results: 25/34 patients had tumor metastasis. 135 non-silent mutations in 62 genes were detected in 27 tumor samples, while 7 patients’ samples had no mutation detected. CDH1, BRCA2 and SMAD4 gene mutations only occurred among metastasis patients. CDH1, BRCA2 and KRAS gene mutations are associated with a lower overall survival rate. Among them, 5 patients had a CDH1 mutation, including one splicing mutation, three frameshift mutations, one non-frameshift mutation and two non-synonymous mutations. All five patients had tumor metastasis, with the survival time less than 17 months, compared with all patients’ average overall survival of 22 month. Conclusions: Previous studies showed that mutation in CDH1 is linked to gastric cancer (GC) susceptibility and tumor invasion. Our results indicated that the mutation of CDH1 was also associated with the prognosis of gastric adenocarcinoma (P < .01) and was an independent factor (P < .05).

Class III β-tubulin as a predictive marker for taxane-based first-line palliative chemotherapy in recurrent or metastatic gastric cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 44-44
Author(s):  
Jun-Eul Hwang ◽  
Dae-Eun Kim ◽  
Hyun-Jeong Shim ◽  
Woo Kyun Bae ◽  
Sang-Hee Cho ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Palliative Chemotherapy ◽  
Predictive Marker ◽  
Metastatic Gastric Cancer ◽  
Class Iii ◽  
First Line ◽  
Gastric Cancer Patients ◽  
Low Expression ◽  
Β Tubulin

44 Background: Class III β tubulin (TUBB3) is a prognostic marker in various tumors and role of TUBB3 in advanced gastric cancer is not clearly defined yet. We analyzed the significance of TUBB3 expression along with ERCC1 in recurrent or metastatic gastric cancer patients receiving taxane based first-line palliative chemotherapy. Methods: We reviewed 146 patients with advanced gastric adenocarcinoma who received taxane based first-line palliative chemotherapy between 2004 and 2010 at Chonnam National University Hwasun hospital. Immunohistochemical stain of TUBB3 and ERCC1 was done in paraffin-embedded tumor tissue. We evaluated response to chemotherapy, progression-free survival (PFS), and overall survival (OS). Results: A total of 146 patients with advanced gastric cancer received docetaxel and cisplatin (n=15), or paclitaxel and cisplatin (n=131) with or without 5-fluorouracil (5-FU). The median PFS was significantly shorter for patients with TUBB3 high expression than patients with TUBB3 low expression (3.63 versus 6.67 months, p=0.001). OS was not associated with TUBB3 expression status (12.9 versus 13.1 months, p=0.769). In multivariate analysis, only TUBB3 was related to shorter PFS (HR 2.74, 95% CI 1.91-3.91, p=0.001). Patients with ERCC1 high expression showed lower response rate than patients with ERCC1 low expression (24% versus 63.2%, p=0.001), however ERCC1 showed no clinical influence on PFS and OS. Conclusions: TUBB3 is a strong predictive marker in recurrent or metastatic gastric cancer patients receiving taxane based first-line palliative chemotherapy. Clinical impact of ERCC1 is not evident in this setting.

scholarly journals Relationship of clinicopathological parameters and preoperative CA19-9 level in patients with gastric cancer

2015 ◽  
Vol 23 (1) ◽  
pp. 60-67
Author(s):  
Laila Shirin ◽  
Md Mizanur Rahman ◽  
Saifuddin Ahmed ◽  
Md Nabir Hossain
Keyword(s):  
Gastric Cancer ◽  
Gastric Carcinoma ◽  
Cancer Patients ◽  
Serum Levels ◽  
Lymph Node Involvement ◽  
Clinicopathological Parameters ◽  
Depth Of Invasion ◽  
Cutoff Value ◽  
Gastric Cancer Patients ◽  
Relationship Of

Objective: This study is an evaluation of serum level of the tumor marker CA 19-9 in gastric cancer patients in preoperative periods to assess the relationship of level of tumor markers in serum and clinicopathological parameters in gastric cancer. Methods: A prospective study was done of 61 patients diagnosed with gastric cancer treated at a single institution in Bangladesh National Institute of Cancer Research and Hospital (NICRH), Dhaka, from July 2010 to December 2011. Analyses were performed to identify patient and tumor-related characteristics in gastric cancer patients. The sera from 61patients with gastric cancer were measured for CA19-9 level using a commercial immunoradiometric assay. All the patients underwent diagnostic imaging with computed tomography (CT) or ultrasound (US) before laparotomy. Metastasis was confirmed by either by US or CT and direct visualization of metastatic deposits after laparotomy. Results: The serum levels of CA 19-9 e” the cutoff value of 40 U/ml was regarded as positive. The serum levels of CA 19-9 d” the cutoff value of 40 U/ml was considered as negative. Clinicopathological factors age, sex, tumor infiltration, N-classification, staging and grading was compared with CA19-9 level in gastric carcinoma. Preoperative levels of CA19-9 was above the cut-off levels in 23% of all cases. In the present study, we found CA 19-9 positivity was not significantly related with age (p.48) & sex (p.35) of the patients. There was no correlation with the histologic type and CA 19-9 positivity (P.19). CA 19-9 positivity had correlation with the proportions of depth of invasion (T stage) (P.007), lymph node involvement (P.000), metastasis (p .03); but no correlation with stage (P .4) in case of gastric carcinoma. DOI: http://dx.doi.org/10.3329/jdmc.v23i1.22696 J Dhaka Medical College, Vol. 23, No.1, April, 2014, Page 60-67

Sign in / Sign up

Export Citation Format

Share Document